Skip to content

Fludrocortisone Acetate

FDA-approved product (tablet, oral), marketed as Florinef, Fludrocortisone Acetate.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Fludrocortisone Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Adrenogenital syndrome
  • Chronic primary adrenal insufficiency
  • Primary adrenal insufficiency

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Mineralocorticoids
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli28.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis29.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Fludrocortisone Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1

    NCT02574910 · start 2017-08-01

    Registered record
    Registry ID
    NCT02574910
    Conditions
    Congenital Adrenal Hyperplasia
    Interventions
    Abiraterone acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2017-08-01
    Completion
    2023-06-03
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCongenital Adrenal Hyperplasia
    InterventionAbiraterone acetate
    PhasePhase 1
    Registry statusTerminated
  • Treatment of Post-SCI Hypotension

    NCT02919917 · start 2017-06-01

    Registered record
    Registry ID
    NCT02919917
    Conditions
    Spinal Cord Injury; Autonomic Dysreflexia; Orthostatic Hypotension; Baroreceptor Integrity; Sympathetic Integrity; Vagal Integrity; Hypotension; Cerebral Blood Flow; Blood Pressure; Venous Occlusion Plethysmography
    Interventions
    Midodrine Hydrochloride; Midodrine Hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2017-06-01
    Completion
    2021-09-01
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSpinal Cord Injury; Autonomic Dysreflexia; Orthostatic Hypotension; Baroreceptor Integrity +6 more
    InterventionMidodrine Hydrochloride; Midodrine Hydrochloride
    PhasePhase 2 / Phase 3
    Registry statusCompleted
  • Impact of the Administration of Fludrocortisone in Very Premature Infants

    NCT03001089 · start 2017-06-01

    Registered record
    Registry ID
    NCT03001089
    Conditions
    Partial Mineralocorticoid Deficiency
    Interventions
    Oral Fludrocortisone (enteral); Placebo Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-06-01
    Completion
    2020-09-08
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPartial Mineralocorticoid Deficiency
    InterventionOral Fludrocortisone (enteral); Placebo Oral Tablet
    PhasePhase 2
    Registry statusCompleted
  • Mineralocorticoid Receptor, NMDA Receptor and Cognitive Function in Depression

    NCT03062150 · start 2016-09-27

    Registered record
    Registry ID
    NCT03062150
    Conditions
    Major Depression
    Interventions
    Placebo; Fludrocortisone; D-Cycloserine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2016-09-27
    Completion
    2019-02-11
    Enrolment
    232

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depression
    InterventionPlacebo; Fludrocortisone; D-Cycloserine
    PhaseNot applicable
    Registry statusCompleted
  • The Role of Minerelocorticoid Receptor on Modulating Aldosterone Production

    NCT02871648 · start 2016-01

    Registered record
    Registry ID
    NCT02871648
    Conditions
    Healthy Volunteers
    Interventions
    Placebo; Fludrocortisone; Eplerenone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-01
    Completion
    2019-12
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionPlacebo; Fludrocortisone; Eplerenone
    PhasePhase 1
    Registry statusCompleted
  • Influence of Polymorphisms in the ATP6V1 Gene of the V-ATPase on the Development of Incomplete Distal Renal Tubular Acidosis

    NCT01690039 · start 2012-09

    Registered record
    Registry ID
    NCT01690039
    Conditions
    Acidosis, Renal Tubular; Nephrolithiasis; Vacuolar Proton-Translocating ATPases
    Interventions
    Furosemide-Fludrocortisone-Test (test for urinary acidification)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-09
    Completion
    2017-05-12
    Enrolment
    170

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcidosis, Renal Tubular; Nephrolithiasis; Vacuolar Proton-Translocating ATPases
    InterventionFurosemide-Fludrocortisone-Test (test for urinary acidification)
    PhaseNot recorded
    Registry statusCompleted
  • Orthostatic Dysregulation and Associated Gastrointestinal Dysfunction in Parkinson's Disease -Treatment

    NCT01993680 · start 2012-06

    Registered record
    Registry ID
    NCT01993680
    Conditions
    Autonomic Disturbances in Parkinson's Disease
    Interventions
    Pyridostigmine bromide; fludrocortisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-06
    Completion
    2016-04-01
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAutonomic Disturbances in Parkinson's Disease
    InterventionPyridostigmine bromide; fludrocortisone
    PhasePhase 2
    Registry statusCompleted
  • Orthostatic Hypotension Treatment on Rehab Unit

    NCT01030874 · start 2011-10

    Registered record
    Registry ID
    NCT01030874
    Conditions
    Orthostatic Hypotension; Falls
    Interventions
    Medication review; Nutrition/Salt intake; Education; Exercise; Drug Recommendations
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2011-10
    Completion
    2016-05
    Enrolment
    356

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOrthostatic Hypotension; Falls
    InterventionMedication review; Nutrition/Salt intake; Education; Exercise +1 more
    PhaseNot applicable
    Registry statusCompleted
  • Fludrocortisone's Test in Salt Sensitivity

    NCT01453959 · start 2011-07

    Registered record
    Registry ID
    NCT01453959
    Conditions
    Hypertension
    Interventions
    Fludrocortisone; Diet cycles
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2011-07
    Completion
    2013-06
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionFludrocortisone; Diet cycles
    PhasePhase 4
    Registry statusUnknown
  • Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus

    NCT00608101 · start 2010-09

    Registered record
    Registry ID
    NCT00608101
    Conditions
    Type 1 Diabetes
    Interventions
    Fludrocortisone; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2010-09
    Completion
    2010-09
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 1 Diabetes
    InterventionFludrocortisone; Dexamethasone
    PhaseNot applicable
    Registry statusWithdrawn
  • Corticosteroid Therapy for Glucocorticoid Insufficiency Related to Traumatic Brain Injury

    NCT01093261 · start 2010-08

    Registered record
    Registry ID
    NCT01093261
    Conditions
    Traumatic Brain Injury; Trauma; Adrenal Insufficiency; Pneumonia
    Interventions
    Placebo; Hydrocortisone Fludrocortisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-08
    Completion
    2012-12
    Enrolment
    336

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTraumatic Brain Injury; Trauma; Adrenal Insufficiency; Pneumonia
    InterventionPlacebo; Hydrocortisone Fludrocortisone
    PhasePhase 3
    Registry statusCompleted
  • Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases

    NCT00623766 · start 2008-07

    Registered record
    Registry ID
    NCT00623766
    Conditions
    Melanoma
    Interventions
    Ipilimumab; Corticosteroid: Betamethasone; Corticosteroid: Dexamethasone; Corticosteroid: Fludrocortisone; Corticosteroid: Hydrocortisone; Corticosteroid: Meprednisone; Corticosteroid: Methylprednisolone; Corticosteroid: Prednisolone; Corticosteroid: Prednisone; Corticosteroid: Triamcinolone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-07
    Completion
    2012-10
    Enrolment
    99

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma
    InterventionIpilimumab; Corticosteroid: Betamethasone; Corticosteroid: Dexamethasone; Corticosteroid: Fludrocortisone +6 more
    PhasePhase 2
    Registry statusCompleted
  • Effects of Fludrocortisone and Hydrocortisone in Healthy Volunteers With Aldosterone Induced Suppression

    NCT00673270 · start 2008-05

    Registered record
    Registry ID
    NCT00673270
    Conditions
    Renin Angiotensin
    Interventions
    Fludrocortisone; Hydrocortisone; Placebo of Fludrocortisone; Placebo of Hydrocortisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2008-05
    Completion
    2009-03
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenin Angiotensin
    InterventionFludrocortisone; Hydrocortisone; Placebo of Fludrocortisone; Placebo of Hydrocortisone
    PhasePhase 1 / Phase 2
    Registry statusTerminated
  • Activated Protein C and Corticosteroids for Human Septic Shock

    NCT00625209 · start 2008-03

    Registered record
    Registry ID
    NCT00625209
    Conditions
    Septic Shock
    Interventions
    placebos; hydrocortisone and fludrocortisone and placebo; recombinant human activated protein C and placebos; recombinant human activated protein C and hydrocortisone and fludrocortisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-03
    Completion
    2016-07
    Enrolment
    1,241

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeptic Shock
    Interventionplacebos; hydrocortisone and fludrocortisone and placebo; recombinant human activated protein C and placebos; recombinant human activated protein C and hydrocortisone and fludrocortisone
    PhasePhase 3
    Registry statusCompleted
  • Combination of Corticotherapy and Intensive Insulin Therapy for Septic Shock

    NCT00320099 · start 2006-01

    Registered record
    Registry ID
    NCT00320099
    Conditions
    Septic Shock
    Interventions
    recombinant human insulin; hydrocortisone; fludrocortisone; Hydrocortisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-01
    Completion
    2009-02
    Enrolment
    508

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeptic Shock
    Interventionrecombinant human insulin; hydrocortisone; fludrocortisone; Hydrocortisone
    PhasePhase 3
    Registry statusCompleted